Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Firuglipel is an orally available and selective agonist of GPR119.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約8-10 週間 | ¥ 418,000 |
50 mg | 約8-10 週間 | ¥ 546,500 |
100 mg | 約8-10 週間 | ¥ 711,500 |
説明 | Firuglipel is an orally available and selective agonist of GPR119. |
In vitro | Firuglipel increases intracellular cAMP in a concentration-dependent manner in rat, human, and mouse GPR119-expressing Chinese hamster ovary (CHO)-K1 cells (EC50: 51.5, 98.4, and 108.1 nM, respectively). Firuglipel has no effect on intracellular cAMP in pcDNA3.1/CHO-K1 cells. |
In vivo | Firuglipel (1-30 mg/kg) upregulates glucagon-like peptide-1. It also enhances glucose-dependent insulin secretion and improves glucose homeostasis in type 2 diabetic rats. |
分子量 | 467.49 |
分子式 | C25H26FN3O5 |
CAS No. | 1371591-51-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Firuglipel 1371591-51-3 Endocrinology/Hormones GPCR/G Protein GPR Inhibitor inhibitor inhibit